Consolidated Financial Statements for the First Quarter Ended June 30, 2018
FY2019 (April 1, 2018 - March 31, 2019) [UNAUDITED]
July 31, 2018
Takara Bio Inc.
Tokyo Stock Exchange (1st section)4974
http://www.takara-bio.co.jp
Koichi Nakao, President
Shuichiro Matsuzaki, Executive Vice President
Tel. (077) 565-6970
Quarterly statement filing date (as planned)
August 10, 2018
Scheduled date of starting delivery of dividends:‐Supplementary documents of the financial results
Yes
Financial results information meeting:
NoNotes: 1. The accompanying financial statements have been prepared in accordance with accounting principles andpractices generally accepted in Japan.
2. Amounts are rounded down to the nearest million yen.
Company name:
Stock exchange listings:
Code number:
URL:
Company representative:
Contact:

1. Results for the three months ended June 30, 2018 (Apr. 1, 2018 – Jun. 31, 2018)(1) Operating results(Percentages indicate changes from the same period of the previous fiscalyear.)Three months ended
Jun. 30, 2018
Net sales
Operating income
Ordinary income
Net income (loss) attributable to owners of theparentNet income per share (in yen)
Fully diluted net income per share (in yen)
Note: Comprehensive income(Millions of yen)
8,847
1,544
1,559
1,032
8.57(495)

Three months ended
Jun. 30, 2017
(%)

(%)

39.2
487.8
442.0
-

(Millions of yen)
6,355
262
287
22

0.8
(59.2)(56.0)(92.0)

-

0.19
(751)

-(2) Financial position

Total assets
Net assets
Equity ratio (%)
Net assets per share (in yen)
(Reference) Equity

As of Jun. 30, 2018
(Millions of yen)

As of Mar. 31, 2018
(Millions of yen)

67,64360,92189.9
505.0960,82068,67061,95990.1
513.6661,852

Partial revision of accounting standard related to tax effect accounting (Article 28 on corporate accounting standard, February
16, 2018) has been applied from the period of the three months ended June 30, 2018. Accordingly, financial position for the year
ended March 31, 2018 indicates the numerical value after retroactive adjustment due to this revision.

2. Dividends
Annual dividends per share in yen
Year ended Mar. 31,
Year ending Mar. 31,
Year ending Mar. 31,
20182019
2019 (Forecast)First quarter end
Second quarter end
0.00
0.00
Third quarter end
Year end
4.50
6.00
Annual4.50
6.00
Note: No revision of dividend payment forecast since the most recently announced payment forecast.

3. Forecast for the year ending March 31, 2019 (Apr. 1, 2018 – Mar. 31, 2019)(Percentages indicated changes from the same period of the previous fiscalyear.)Six months ending
Sep. 30, 2018Year ending Mar. 31, 2019

(Millions of yen)(%)
(Millions of yen)
Net sales
17,75525.7
36,800Operating income
2,500
263.1
5,000
Ordinary income
2,557
233.8
5,200
Net income attributable to owners of the1,646
444.1
3,100
parent
Net income attributable to owners of the13.68
25.74
parent per share (in yen)
Note: No revision of financial forecast since the most recently announced financial forecast.

(%)
13.9
40.6
34.6
32.8

4. Others(1) Changes in subsidiaries during the three months ended Jun. 30, 2018
(Changes in specified subsidiaries resulting in change of scope) ： No
Newly included: - (Name)
Excluded: - (Name)(2) Application of special accounting methods to the consolidated quarterly financial statements： No(3) Changes in accounting policies, changes in accounting estimates, and retrospective restatement
1) Changes based on revisions of accounting standard： No
2) Changes other than ones based on revisions of accounting standard： No
3) Changes in accounting estimates： No4) Restatement： No(4) Number of outstanding shares (Common stock)1) Number of outstanding shares at year end (Treasury stocks are included)
120,415,600
As of June 30, 2018
120,415,600
As of March 31, 2018
2) Number of treasury stocks at year end
As of June 30, 2018
As of March 31, 2018
3) Average number of outstanding shares (Quarterly total)
120,415,600
As of June 30, 2018
As of June 30, 2017
120,415,600
These quarterly financial statements are not subject to auditing.
Comment regarding appropriate use of earnings forecasts and other special notes
Forward-looking statements contained in this document are determined by the Takara Bio Group based on information
currently available to the Group and include a number of uncertainties. Actual results could differ from these forecasts
due to changes in conditions that occur in the future. For information regarding the above, please refer to 1. Qualitative
Information for the three months ended June 30, 2018 (4) Qualitative Information Regarding Consolidated Forecasts, on
page 3 of the attached document.
(Change in calendar indication)
Calendar indication has been changed from Japanese style to western style since Consolidated Financial Statements forthe first quarter ended June 30, 2018.